Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.

JAMA oncology

Raphael MJ, Robinson A, Booth CM, O'Donnell J, Palmer M, Eisenhauer E, Brundage M.
PMID: 31556921
JAMA Oncol. 2019 Dec 01;5(12):1779-1789. doi: 10.1001/jamaoncol.2019.3338.

IMPORTANCE: It is unclear whether patients with advanced cancer value surrogate end points, particularly progression-free survival (PFS). Despite this uncertainty, surrogate end points form the basis of regulatory approval for the majority of new cancer treatments.OBJECTIVE: To summarize and...

Cite
Raphael MJ, Robinson A, Booth CM, et al. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA Oncol. 2019;5(12):1779-1789doi: 10.1001/jamaoncol.2019.3338.
Raphael, M. J., Robinson, A., Booth, C. M., O'Donnell, J., Palmer, M., Eisenhauer, E., & Brundage, M. (2019). The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA oncology, 5(12), 1779-1789. https://doi.org/10.1001/jamaoncol.2019.3338
Raphael, Michael J, et al. "The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature." JAMA oncology vol. 5,12 (2019): 1779-1789. doi: https://doi.org/10.1001/jamaoncol.2019.3338
Raphael MJ, Robinson A, Booth CM, O'Donnell J, Palmer M, Eisenhauer E, Brundage M. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA Oncol. 2019 Dec 01;5(12):1779-1789. doi: 10.1001/jamaoncol.2019.3338. PMID: 31556921.
Copy Download .nbib Format: NLM
Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma.

Journal of cancer research and clinical oncology

Nomura K, Aokage K, Nakai T, Sakashita S, Miyoshi T, Tane K, Samejima J, Suzuki K, Tsuboi M, Ishii G.
PMID: 33811275
J Cancer Res Clin Oncol. 2021 Dec;147(12):3699-3707. doi: 10.1007/s00432-021-03608-4. Epub 2021 Apr 02.

PURPOSE: Lymph node involvement is one of the important prognostic factors of patients with lung adenocarcinoma. In the tumor, node, and metastasis classification, lymph node involvement is categorized only according to the anatomical station and not the involvement pattern....

Cite
Nomura K, Aokage K, Nakai T, et al. Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. J Cancer Res Clin Oncol. 2021;147(12):3699-3707doi: 10.1007/s00432-021-03608-4.
Nomura, K., Aokage, K., Nakai, T., Sakashita, S., Miyoshi, T., Tane, K., Samejima, J., Suzuki, K., Tsuboi, M., & Ishii, G. (2021). Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. Journal of cancer research and clinical oncology, 147(12), 3699-3707. https://doi.org/10.1007/s00432-021-03608-4
Nomura, Kotaro, et al. "Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma." Journal of cancer research and clinical oncology vol. 147,12 (2021): 3699-3707. doi: https://doi.org/10.1007/s00432-021-03608-4
Nomura K, Aokage K, Nakai T, Sakashita S, Miyoshi T, Tane K, Samejima J, Suzuki K, Tsuboi M, Ishii G. Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. J Cancer Res Clin Oncol. 2021 Dec;147(12):3699-3707. doi: 10.1007/s00432-021-03608-4. Epub 2021 Apr 02. PMID: 33811275.
Copy Download .nbib Format: NLM
The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours.

Acta oncologica (Stockholm, Sweden)

Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E, Ravaud A, Domblides C, Daste A.
PMID: 34549686
Acta Oncol. 2021 Dec;60(12):1597-1603. doi: 10.1080/0284186X.2021.1978540. Epub 2021 Sep 22.

BACKGROUND: Evidence suggests that sarcopenia is a significant predictive factor of worst outcomes and treatment-associated toxicities in patients with metastatic solid tumours. The aim of this study was to explore the relationship between low muscle mass and clinical outcomes...

Cite
Haik L, Gonthier A, Quivy A, et al. The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol. 2021;60(12):1597-1603doi: 10.1080/0284186X.2021.1978540.
Haik, L., Gonthier, A., Quivy, A., Gross-Goupil, M., Veillon, R., Frison, E., Ravaud, A., Domblides, C., & Daste, A. (2021). The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta oncologica (Stockholm, Sweden), 60(12), 1597-1603. https://doi.org/10.1080/0284186X.2021.1978540
Haik, Laura, et al. "The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours." Acta oncologica (Stockholm, Sweden) vol. 60,12 (2021): 1597-1603. doi: https://doi.org/10.1080/0284186X.2021.1978540
Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E, Ravaud A, Domblides C, Daste A. The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol. 2021 Dec;60(12):1597-1603. doi: 10.1080/0284186X.2021.1978540. Epub 2021 Sep 22. PMID: 34549686.
Copy Download .nbib Format: NLM
Progression-free survival (PFS) in oncology: caveat emptor!.

Basic & clinical pharmacology & toxicology

Sarac SB, Ainsworth MA, Hovgaard D, Bjerrum OW.
PMID: 30672131
Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):237-238. doi: 10.1111/bcpt.13192. Epub 2019 Jan 22.

No abstract available.

Cite
Sarac SB, Ainsworth MA, Hovgaard D, et al. Progression-free survival (PFS) in oncology: caveat emptor!. Basic Clin Pharmacol Toxicol. 2019;124(3):237-238doi: 10.1111/bcpt.13192.
Sarac, S. B., Ainsworth, M. A., Hovgaard, D., & Bjerrum, O. W. (2019). Progression-free survival (PFS) in oncology: caveat emptor!. Basic & clinical pharmacology & toxicology, 124(3), 237-238. https://doi.org/10.1111/bcpt.13192
Sarac, Sinan B, et al. "Progression-free survival (PFS) in oncology: caveat emptor!." Basic & clinical pharmacology & toxicology vol. 124,3 (2019): 237-238. doi: https://doi.org/10.1111/bcpt.13192
Sarac SB, Ainsworth MA, Hovgaard D, Bjerrum OW. Progression-free survival (PFS) in oncology: caveat emptor!. Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):237-238. doi: 10.1111/bcpt.13192. Epub 2019 Jan 22. PMID: 30672131.
Copy Download .nbib Format: NLM
Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis.

Critical reviews in oncology/hematology

Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, Petrelli F.
PMID: 34343657
Crit Rev Oncol Hematol. 2021 Sep;165:103434. doi: 10.1016/j.critrevonc.2021.103434. Epub 2021 Jul 31.

BACKGROUND: The role of immune checkpoint inhibitors (ICI) rechallenge in cancer patients is not defined. When ICIs are discontinued due to treatment completion or toxicity, another course of ICIs is feasible in clinical practice, but the amount of data...

Cite
Inno A, Roviello G, Ghidini A, et al. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;165:103434doi: 10.1016/j.critrevonc.2021.103434.
Inno, A., Roviello, G., Ghidini, A., Luciani, A., Catalano, M., Gori, S., & Petrelli, F. (2021). Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Critical reviews in oncology/hematology, 165103434. https://doi.org/10.1016/j.critrevonc.2021.103434
Inno, Alessandro, et al. "Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis." Critical reviews in oncology/hematology vol. 165 (2021): 103434. doi: https://doi.org/10.1016/j.critrevonc.2021.103434
Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, Petrelli F. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021 Sep;165:103434. doi: 10.1016/j.critrevonc.2021.103434. Epub 2021 Jul 31. PMID: 34343657.
Copy Download .nbib Format: NLM
Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!".

Basic & clinical pharmacology & toxicology

Bergmann TK, Christensen MMH, Haastrup MB, Damkier P.
PMID: 30747495
Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):239. doi: 10.1111/bcpt.13200.

No abstract available.

Cite
Bergmann TK, Christensen MMH, Haastrup MB, et al. Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!". Basic Clin Pharmacol Toxicol. 2019;124(3):239doi: 10.1111/bcpt.13200.
Bergmann, T. K., Christensen, M. M. H., Haastrup, M. B., & Damkier, P. (2019). Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!". Basic & clinical pharmacology & toxicology, 124(3), 239. https://doi.org/10.1111/bcpt.13200
Bergmann, Troels K, et al. "Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!"." Basic & clinical pharmacology & toxicology vol. 124,3 (2019): 239. doi: https://doi.org/10.1111/bcpt.13200
Bergmann TK, Christensen MMH, Haastrup MB, Damkier P. Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!". Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):239. doi: 10.1111/bcpt.13200. PMID: 30747495.
Copy Download .nbib Format: NLM
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.

Oncoimmunology

Carretero-González A, Otero I, Lora D, Carril-Ajuria L, Castellano D, de Velasco G.
PMID: 33680572
Oncoimmunology. 2021 Feb 23;10(1):1878599. doi: 10.1080/2162402X.2021.1878599.

Immune checkpoint inhibitors (ICIs) as monotherapy in different solid tumors showed an early detrimental effect in a subset of patients reflected by the early crossover of the progression-free survival (PFS) curves. Currently, combination therapies with ICIs added to chemotherapy...

Cite
Carretero-González A, Otero I, Lora D, et al. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Oncoimmunology. 2021;10(1):1878599doi: 10.1080/2162402X.2021.1878599.
Carretero-González, A., Otero, I., Lora, D., Carril-Ajuria, L., Castellano, D., & de Velasco, G. (2021). Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Oncoimmunology, 10(1), 1878599. https://doi.org/10.1080/2162402X.2021.1878599
Carretero-González, Alberto, et al. "Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis." Oncoimmunology vol. 10,1 (2021): 1878599. doi: https://doi.org/10.1080/2162402X.2021.1878599
Carretero-González A, Otero I, Lora D, Carril-Ajuria L, Castellano D, de Velasco G. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Oncoimmunology. 2021 Feb 23;10(1):1878599. doi: 10.1080/2162402X.2021.1878599. PMID: 33680572; PMCID: PMC7906255.
Copy Download .nbib Format: NLM
[Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Yin ZX, He XL, He J, Tian X, Zhu CG, Chen KK, Zou RY, You YL, Jiang XP, Tang WF, Zeng MH, Huang ZJ, Yao AQ.
PMID: 33627213
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Feb;23(2):169-173.

OBJECTIVE: To study the long-term clinical effect of multicenter multidisciplinary treatment (MDT) in children with renal malignant tumors.METHODS: A retrospective analysis was performed on the medical data of 55 children with renal malignant tumors who were diagnosed and treated...

Cite
Yin ZX, He XL, He J, et al. [Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors]. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(2):169-173
Yin, Z. X., He, X. L., He, J., Tian, X., Zhu, C. G., Chen, K. K., Zou, R. Y., You, Y. L., Jiang, X. P., Tang, W. F., Zeng, M. H., Huang, Z. J., & Yao, A. Q. (2021). [Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 23(2), 169-173.
Yin, Ze-Xi, et al. "[Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors]." Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics vol. 23,2 (2021): 169-173.
Yin ZX, He XL, He J, Tian X, Zhu CG, Chen KK, Zou RY, You YL, Jiang XP, Tang WF, Zeng MH, Huang ZJ, Yao AQ. [Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors]. Zhongguo Dang Dai Er Ke Za Zhi. 2021 Feb;23(2):169-173. Chinese. PMID: 33627213; PMCID: PMC7921527.
Copy Download .nbib Format: NLM
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

ESMO open

Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A.
PMID: 34303929
ESMO Open. 2021 Aug;6(4):100220. doi: 10.1016/j.esmoop.2021.100220. Epub 2021 Jul 22.

BACKGROUND: Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low incidence, the prognosis of IBC at metastatic stage is...

Cite
Dano D, Lardy-Cleaud A, Monneur A, et al. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open. 2021;6(4):100220doi: 10.1016/j.esmoop.2021.100220.
Dano, D., Lardy-Cleaud, A., Monneur, A., Quenel-Tueux, N., Levy, C., Mouret-Reynier, M. A., Coudert, B., Mailliez, A., Ferrero, J. M., Guiu, S., Campone, M., de La Motte Rouge, T., Petit, T., Pistilli, B., Dalenc, F., Simon, G., Lerebours, F., Chabaud, S., Bertucci, F., & Gonçalves, A. (2021). Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO open, 6(4), 100220. https://doi.org/10.1016/j.esmoop.2021.100220
Dano, D, et al. "Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)." ESMO open vol. 6,4 (2021): 100220. doi: https://doi.org/10.1016/j.esmoop.2021.100220
Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open. 2021 Aug;6(4):100220. doi: 10.1016/j.esmoop.2021.100220. Epub 2021 Jul 22. PMID: 34303929; PMCID: PMC8327489.
Copy Download .nbib Format: NLM
Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.

The British journal of dermatology

Thompson LL, Li EB, Krasnow NA, Chang MS, Said JT, Molina GE, Polyakov NJ, Yoon J, Dee EC, Huang K, Blum AE, Kuchroo JR, Hinton AN, Reynolds KL, Chen ST.
PMID: 33733456
Br J Dermatol. 2021 Sep;185(3):627-635. doi: 10.1111/bjd.20074. Epub 2021 May 17.

BACKGROUND: Cutaneous immune-related adverse events (cirAEs) are a common side-effect of immune checkpoint inhibitors (ICIs). However, prior work examining these toxicities in detail has considered only the fraction of events evaluated by dermatologists. Associations between dermatology referral, cirAE treatment...

Cite
Thompson LL, Li EB, Krasnow NA, et al. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol. 2021;185(3):627-635doi: 10.1111/bjd.20074.
Thompson, L. L., Li, E. B., Krasnow, N. A., Chang, M. S., Said, J. T., Molina, G. E., Polyakov, N. J., Yoon, J., Dee, E. C., Huang, K., Blum, A. E., Kuchroo, J. R., Hinton, A. N., Reynolds, K. L., & Chen, S. T. (2021). Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. The British journal of dermatology, 185(3), 627-635. https://doi.org/10.1111/bjd.20074
Thompson, L L, et al. "Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity." The British journal of dermatology vol. 185,3 (2021): 627-635. doi: https://doi.org/10.1111/bjd.20074
Thompson LL, Li EB, Krasnow NA, Chang MS, Said JT, Molina GE, Polyakov NJ, Yoon J, Dee EC, Huang K, Blum AE, Kuchroo JR, Hinton AN, Reynolds KL, Chen ST. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol. 2021 Sep;185(3):627-635. doi: 10.1111/bjd.20074. Epub 2021 May 17. PMID: 33733456.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries